Predicting the Success of HPV Vaccines

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-10-25-2005
Volume 0
Issue 0

Will vaccines against cervical cancer be the blockbusters that Merck and GSK are predicting? Or will issues of cost-effectiveness and parental reluctance hold them back? The experts weigh in on the debate.

Related Videos
Jason Tate, FSP Talent Strategy Lead, PPD, part of Thermo Fisher Scientific
Related Content